---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-024752"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:49:39.859496+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# InMed to wind down BayMedica commercial ops; focus shifts to Alzheimer's, AMD pipeline

## Summary
- Board ratified wind-down of BayMedica commercial operations due to H.R. 5371 uncertainty; completion expected by June 30, 2026.
- Estimated severance costs of ~$550K and other expenses ~$120K; partially offset by product sale profits during wind-down.
- Company will focus exclusively on INM-901 (Alzheimer's) and INM-089 (dry AMD) drug candidates; commercial revenue stream eliminated.
- Pro forma financial statements treat BayMedica as discontinued operations; revenue from commercial ops reduced to $0.

## SEC filing metadata
- accession: 0001213900-26-024752
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390026024752/0001213900-26-024752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390026024752/ea0279869-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-024752
- JSON: https://secwatch.observer/filing/0001213900-26-024752.json
- Plain text: https://secwatch.observer/filing/0001213900-26-024752.txt

## Key facts
- Restructurings & Charges
  InMed Pharmaceuticals Inc. announced a restructuring with charges of severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000 affecting BayMedica LLC commercial operations business segment.
  - Type: restructuring
  - Charge: severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000
  - Affected area: BayMedica LLC commercial operations business segment
  source text: In connection with the wind down of commercial operations, BayMedica is expected to incur severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000 through the end of the fiscal year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390026024752/0001213900-26-024752-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.